Attached files
| file | filename |
|---|---|
| EX-10.11 - EX-10.11 - Deciphera Pharmaceuticals, Inc. | d364141dex1011.htm |
| EX-10.10 - EX-10.10 - Deciphera Pharmaceuticals, Inc. | d364141dex1010.htm |
| EX-10.5 - EX-10.5 - Deciphera Pharmaceuticals, Inc. | d364141dex105.htm |
| EX-10.4 - EX-10.4 - Deciphera Pharmaceuticals, Inc. | d364141dex104.htm |
| EX-10.3 - EX-10.3 - Deciphera Pharmaceuticals, Inc. | d364141dex103.htm |
| EX-10.2 - EX-10.2 - Deciphera Pharmaceuticals, Inc. | d364141dex102.htm |
| EX-4.1 - EX-4.1 - Deciphera Pharmaceuticals, Inc. | d364141dex41.htm |
| EX-3.4 - EX-3.4 - Deciphera Pharmaceuticals, Inc. | d364141dex34.htm |
| EX-3.2 - EX-3.2 - Deciphera Pharmaceuticals, Inc. | d364141dex32.htm |
| EX-1.1 - EX-1.1 - Deciphera Pharmaceuticals, Inc. | d364141dex11.htm |
| S-1/A - AMENDMENT NO. 3 - Deciphera Pharmaceuticals, Inc. | d364141ds1a.htm |
Exhibit 21
| Legal Name |
State of Organization | |
| DP MergerSub, LLC1 |
Delaware | |
| NLV-3 MergerSub, Inc.2 |
Delaware | |
| NLV-G MergerSub, Inc.2 |
Delaware | |
| SVLS MergerSub, Inc.2 |
Delaware | |
| DRAGSA20 MergerSub, Inc.2 |
Delaware | |
| Redmile MergerSub, Inc.2 |
Delaware | |
| Deciphera Pharmaceuticals, LLC3 |
Delaware | |
| DRAGSA 20 LLC4 |
Delaware | |
| NLV-3 Deciphera, Inc.4 |
Delaware | |
| NLV-G Deciphera, Inc.4 |
Delaware | |
| SVLS-Deciphera, Inc.4 |
Delaware | |
| Redmile Deciphera Holdings, Inc.4 |
Delaware | |
| 1 | This entity will merge with and into Deciphera Pharmaceuticals, LLC immediately prior the completion of this offering and will no longer be a subsidiary of Deciphera Pharmaceuticals, Inc. at the completion of this offering. |
| 2 | This entity will merge with and into the blocker entities immediately prior the completion of this offering and will no longer be a subsidiary of Deciphera Pharmaceuticals, Inc. at the completion of this offering. |
| 3 | Deciphera Pharmaceuticals, LLC will become a wholly owned subsidiary, directly and indirectly, of Deciphera Pharmaceuticals, Inc. upon the Conversion. |
| 4 | This entity will become a wholly owned subsidiary of Deciphera Pharmaceuticals, Inc. upon the Conversion. |